Kazakhstan delays digital signatures for doctors amid workflow concerns
Kazakhstan delays digital signatures for doctors amid workflow concerns
Kazakhstan delays digital signatures for doctors amid workflow concerns
Kazakhstan's Minister of Health, Akmara Alynazarova, has delayed the rollout of electronic signatures (ES) for medical records. The decision comes after doctors raised concerns about the current system's inefficiency. Under existing rules, they must sign each action or entry individually, creating unnecessary delays.
The original plan required all medical staff to use digital signatures by 1 February 2026. However, the current process forces doctors to authenticate every operation or note in a patient's file. This repetitive signing has proven cumbersome and time-consuming.
The updated system aims to simplify the workflow. Instead of multiple news, doctors will log in once per session, reducing clicks and saving time. Officials also confirmed that the new model will only launch after thorough testing of IT solutions and interface improvements.
The digital signature itself will remain a key tool for preventing fraud. It will help block unauthorised prescriptions and falsified records. Yet, no details have emerged about a further simplified version or a revised implementation date.
The postponement means doctors will continue using the old system for now. Authorities have stressed that convenience and IT readiness must come first. The final switch to the new format will depend on ensuring a smooth, one-click process for medical staff.
Geesthacht Hospital shifts to specialist clinic after financial crisis and staff shortages
A once-full-service hospital now fights for survival. How Geesthacht's bold downsizing could redefine local healthcare—or leave patients scrambling.
National health hotline cuts wait times with 24/7 support and AI upgrades
Struggling with long-term illness? This free hotline now answers faster—thanks to AI and smarter systems. See how it's changing patient care.
Novartis bets $3B on unproven breast cancer therapy SNV4818
A $3B gamble on an untested drug could redefine breast cancer care—or backfire. Why Novartis is banking on SNV4818's untapped potential before clinical trials even begin.
How prior authorization delays can harm patients and frustrate doctors
A system meant to cut costs is putting patients at risk. Doctors warn that insurance red tape is delaying care—and even forcing dangerous medication switches.